Clinical management of autoimmune hepatitis
Standard
Clinical management of autoimmune hepatitis. / Pape, Simon; Schramm, Christoph; Gevers, Tom Jg.
In: UNITED EUR GASTROENT, Vol. 7, No. 9, 11.2019, p. 1156-1163.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Clinical management of autoimmune hepatitis
AU - Pape, Simon
AU - Schramm, Christoph
AU - Gevers, Tom Jg
N1 - © Author(s) 2019.
PY - 2019/11
Y1 - 2019/11
N2 - Autoimmune hepatitis is a rare and chronic liver disease that is characterised by increased serum transaminases and immunoglobulin G, inflammatory liver histology and presence of circulating autoantibodies. An autoimmune hepatitis diagnosis justifies life-long treatment in most patients in order to prevent development of cirrhosis and end-stage liver disease. The cornerstone of treatment is steroid induction therapy followed by maintenance therapy with azathioprine, which is effective in most cases. For patients who do not respond to standard treatment, second-line treatment with other immunosuppressants can be effective. Treatment should be aimed at biochemical remission of the disease, which is defined as normalization of transaminases and immunoglobulin G. Patients should be monitored intensively during the first months of treatment in order to monitor side-effects, assess symptoms and individualise treatment. Specialist consultation should be sought in difficult-to-treat patients. Future studies and networking initiatives should result in optimization of current treatment strategies in autoimmune hepatitis.
AB - Autoimmune hepatitis is a rare and chronic liver disease that is characterised by increased serum transaminases and immunoglobulin G, inflammatory liver histology and presence of circulating autoantibodies. An autoimmune hepatitis diagnosis justifies life-long treatment in most patients in order to prevent development of cirrhosis and end-stage liver disease. The cornerstone of treatment is steroid induction therapy followed by maintenance therapy with azathioprine, which is effective in most cases. For patients who do not respond to standard treatment, second-line treatment with other immunosuppressants can be effective. Treatment should be aimed at biochemical remission of the disease, which is defined as normalization of transaminases and immunoglobulin G. Patients should be monitored intensively during the first months of treatment in order to monitor side-effects, assess symptoms and individualise treatment. Specialist consultation should be sought in difficult-to-treat patients. Future studies and networking initiatives should result in optimization of current treatment strategies in autoimmune hepatitis.
U2 - 10.1177/2050640619872408
DO - 10.1177/2050640619872408
M3 - SCORING: Review article
C2 - 31700628
VL - 7
SP - 1156
EP - 1163
JO - UNITED EUR GASTROENT
JF - UNITED EUR GASTROENT
SN - 2050-6406
IS - 9
ER -
